Osaic Holdings’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
Other funds holding LCTX
Osaic Holdings's LCTX Position: Q3 2026 in Review
Osaic Holdings reduced its Lineage Cell Therapeutics (LCTX) stake by 0.09% in Q3 2026, selling an estimated $2 and leaving 2,180 shares worth $2.07K. The position accounts for ﹤0.01% of the portfolio, ranked #7317.
Osaic Holdings first reported a position in LCTX in Q1 2020 and has held it in 27 quarters since. The position peaked at $123K in Q3 2025. 143 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.
- Osaic Holdings held 2,180 shares of Lineage Cell Therapeutics worth $2.07K as of Q3 2026.
- Osaic Holdings sold 2 Lineage Cell Therapeutics shares in Q3 2026, an estimated $2.
- Lineage Cell Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q3 2026, its #7317 holding.
- Osaic Holdings first reported a position in Lineage Cell Therapeutics in Q1 2020 and has held it in 27 quarters since.
- Osaic Holdings's Lineage Cell Therapeutics position peaked at $123K in Q3 2025.
- 143 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.
Based on Osaic Holdings's 13F filing for Q3 2026, filed 12 Nov 2026.